KRAS G12D inhibitors will benefit never smokers with NSCLC for whom the mutation rate is 55.7% (Figure 2d) and could be a game-changer in PDAC and colorectal carcinoma, where the mutation rates are 67.6% and 39%, respectively. Here, KRAS is linked to non-small cell lung carcinoma.